Clinical lens advantage Axon Optics offers Avulux Migraine and Light Sensitivity Lenses, a clinically proven solution to block harmful light wavelengths that trigger migraines, presenting a strong value proposition for clinicians, optometrists, and eyewear retailers serving migraine patients.

Strategic merger The 2023 merger with Avulux signals expanded IP, broader product reach, and potential cross-selling opportunities; sales outreach can target both existing Axon Optics customers and Avulux channels to accelerate adoption.

Niche market positioning Small team size but focused niche in migraine and light sensitivity eyewear positions the company for targeted partnerships with headache clinics, sleep study centers, and digital health platforms tracking migraine triggers.

Clinical validation Experience with HIT-6 surveys and clinical proof points provides conversation anchors for B2B pitches to clinicians and researchers seeking validated outcomes tied to quality of life and reduced migraine impact.

Digital and e-commerce readiness Tech stack includes WordPress and e-commerce integrations; explore partnerships with ophthalmology clinics, medical distributors, and online retailers to expand distribution and patient access to Avulux lenses.